Literature DB >> 24888272

Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

T Barbui1, J Thiele2, H M Kvasnicka3, A Carobbio1, A M Vannucchi4, A Tefferi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24888272     DOI： 10.1038/leu.2014.175

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

Authors:  Mary F McMullin; D Bareford; P Campbell; A R Green; Claire Harrison; Beverley Hunt; D Oscier; M I Polkey; J T Reilly; E Rosenthal; Kate Ryan; T C Pearson; Bridget Wilkins
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

2.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

3.  Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Authors:  Tiziano Barbui; Jürgen Thiele; Alessandra Carobbio; Paola Guglielmelli; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

Review 4.  An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.

Authors:  A Tefferi; J Thiele; A M Vannucchi; T Barbui
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

5.  Calreticulin mutations and long-term survival in essential thrombocythemia.

Authors:  A Tefferi; E A Wassie; T L Lasho; C Finke; A A Belachew; R P Ketterling; C A Hanson; A Pardanani; N Gangat; A P Wolanskyj
Journal:  Leukemia       Date:  2014-05-05       Impact factor: 11.528

6.  Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.

Authors:  Richard T Silver; William Chow; Attilio Orazi; Stephen P Arles; Stanley J Goldsmith
Journal:  Blood       Date:  2013-07-30       Impact factor: 22.113

7.  Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.

Authors:  Jurgen Thiele; Hans Michael Kvasnicka; Volker Diehl
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

Review 8.  Diagnostic impact of bone marrow histopathology in polycythemia vera (PV).

Authors:  J Thiele; H M Kvasnicka
Journal:  Histol Histopathol       Date:  2005-01       Impact factor: 2.303

9.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  3 in total

1.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

2.  Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

Authors:  Richard T Silver; Spencer Krichevsky
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 3.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.